Business Context and Reporting Period
This Form 8-K is a current report filed by ReWalk Robotics Ltd. (noting the input metadata reference to "Lifeward Ltd." appears to be an error as the filing explicitly names ReWalk Robotics) on October 19, 2020. The report covers events occurring on October 14, 2020, and October 19, 2020. The company is incorporated in Israel and trades on the Nasdaq Capital Market under the symbol RWLK.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The primary material change reported is a corporate governance update:
- Appointment of Director: On October 14, 2020, the Board appointed Ms. Randel E. Richner as a Class II Director, effective November 1, 2020.
- Reason for Appointment: Ms. Richner was appointed to fill a vacancy on the Board.
- Background: Ms. Richner brings over 30 years of experience in health policy, reimbursement, and economics, including prior roles at Intralign Health, Neocure Group, and Boston Scientific Corporation.
Guidance, Outlook, and Risks
Compensation and Arrangements: Ms. Richner will receive standard compensation for non-employee directors as disclosed in the Company's definitive proxy statement filed on May 12, 2020. She has also entered into a standard indemnification agreement and will be covered under the Company's directors' and officers' liability insurance policy.
Regulatory Disclosure: The filing includes a press release regarding the appointment under Item 7.01 (Regulation FD Disclosure). The filing explicitly states that the press release is furnished and not "filed" for purposes of Section 18 of the Exchange Act.
Risks and Contingencies: No specific financial risks, contingencies, or unusual items are disclosed in this report. The filing confirms no undisclosed transactions requiring disclosure under Item 404(a) of Regulation S-K and no family relationships between Ms. Richner and other directors or officers.
Investor Verification Checklist
- Verify the effective date of Ms. Richner's appointment (November 1, 2020) against the company's official board roster.
- Review the Company's definitive proxy statement (Schedule 14A filed May 12, 2020) to confirm the specific compensation package for non-employee directors.
- Confirm that Ms. Richner has not yet been assigned to any specific Board committees as of the filing date.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.